-
No.
Category
Subject
Writer
Date
-
No.
17
SNB-101
Government Support for Promising SCLC Treatment
관리자
2025-07-16
-
No.
16
SNB-101
Domestic New Drug FDA ODD: Path to Approval?
관리자
2025-05-21
-
No.
15
SNB-101
SNB-101 Propels to Phase 2 with FDA IND Clearance
관리자
2025-01-10
-
No.
14
SNB-101
희귀약·패스트트랙 제도, 美 FDA 신약 허가기간 단축 열쇠
관리자
2024-06-13
-
No.
13
SNB-101
EMA grants an ODD for SNB-101 on SCLC
관리자
2024-06-03
-
No.
12
SNB-101
Investigational Drug Access Policy
관리자
2024-05-17
-
No.
11
SNB-101
Fast Track Designation for Small Cell Lung Cancer(FDA)
관리자
2024-05-10
-
No.
10
SNB-101
Orphan Drug Designation(FDA) for SNB-101 on Pancreatic Cancer
관리자
2024-03-04
-
No.
9
SNB-101
Phase 1 Study Results of SNB-101 at ESMO
관리자
2023-10-30
-
No.
8
SNB-101
Orphan Drug Designation(FDA) of SNB-101 for Small Cell Lung Cancer
관리자
2023-07-21
-
No.
7
SNA-001
SN BioScience and Boryung Announce the Licensing Agreement on Generic Version of Abraxane
관리자
2023-01-27
-
No.
6
SNA-001
알부민 나노입자 항암제 국내 1상 신청
관리자
2021-11-12
-
No.
5
SNB-101
이중나노미셀 기술 “미국, 유럽 특허등록”
관리자
2021-07-22
-
No.
4
SNB-101
Boryung to market SN BioScience's nanoparticle anticancer therapy
관리자
2021-02-24
-
No.
3
SNB-101
나노항암제 국내 1상 “첫 환자 투여”
관리자
2020-11-18
-
No.
2
SN BioScience
125억 시리즈B "나노항암제 韓·美 임상"
관리자
2020-07-02
-
No.
1
SN BioScience
S. Korea’s OCI invests $4.4mn in local bio tech startup SN BioScience
관리자
2019-01-22
News
- News
- Latest News